Gu Jin, Chen Pengju
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Colorectal Cancer Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Oct;18(10):974-8.
The diagnosis and treatment of colorectal cancer is one of the main diseases of gastrointestinal surgeons. It is very important to master the adjuvant chemotherapy of colorectal cancer for gastrointestinal surgeons. In recent years, with the development of a number of clinical trials and the appearance of new drugs, fluorouracil combined with oxaliplatin had been established as the standard regimen of adjuvant chemotherapy for colorectal cancer. In the current guidelines, stage III( colon cancer is the indication for adjuvant chemotherapy, while stage II( colon cancer should receive adjuvant chemotherapy is uncertain. Unlike colon cancer, adjuvant therapy of rectal cancer is not evidence-based. Especially, the indication and duration of adjuvant chemotherapy for rectal cancer after neoadjuvant chemoradiotherapy remain controversial. Adjuvant therapy of colorectal cancer still needs further investigation.
结直肠癌的诊断与治疗是胃肠外科医生的主要疾病之一。对于胃肠外科医生而言，掌握结直肠癌的辅助化疗非常重要。近年来，随着多项临床试验的开展和新药的出现，氟尿嘧啶联合奥沙利铂已成为结直肠癌辅助化疗的标准方案。在当前指南中，III期结肠癌是辅助化疗的适应证，而II期结肠癌是否应接受辅助化疗尚不确定。与结肠癌不同，直肠癌的辅助治疗缺乏循证依据。特别是，新辅助放化疗后直肠癌辅助化疗的适应证和疗程仍存在争议。结直肠癌的辅助治疗仍需进一步研究。
